Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Feb;90(2):179.
doi: 10.1002/ajh.23775. Epub 2014 Jun 20.

Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia

Gabriel Mannis  1 , Davina Wu, Tiffany Dea, Theodora Mauro, Gerald Hsu
Affiliations
Case Reports

Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia

Gabriel Mannis et al. Am J Hematol. 2015 Feb.
No abstract available

PubMed Disclaimer

Figures

Image 1
Image 1
Painless, non-pruritic edematous papules on the trunk of a patient who developed an ibrutinib-related rash. Lesions began on the wrists and arms and subsequently generalized to the entire body.
See this image and copyright information in PMC

References

    1. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. NEJM. 2013;369:32–42. - PMC - PubMed
    1. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multi-center, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58. - PMC - PubMed
    1. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. NEJM. 2013;369:507–516. - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts